Published in J Clin Oncol on October 01, 2005
Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes (2009) 2.05
Implementing a geriatric assessment in cooperative group clinical cancer trials: CALGB 360401. J Clin Oncol (2011) 1.76
Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: an analysis of RTOG 9801. J Clin Oncol (2009) 1.34
Role of age and health in treatment recommendations for older adults with breast cancer: the perspective of oncologists and primary care providers. J Clin Oncol (2008) 1.34
Relationship between deficits in overall quality of life and non-small-cell lung cancer survival. J Clin Oncol (2012) 1.33
Age, severe comorbidity and functional impairment independently contribute to poor survival in cancer patients. J Cancer Res Clin Oncol (2007) 1.33
Senior adult oncology. J Natl Compr Canc Netw (2012) 1.20
Optimal management of elderly cancer patients: usefulness of the Comprehensive Geriatric Assessment. Clin Interv Aging (2014) 1.17
Physical performance and subsequent disability and survival in older adults with malignancy: results from the health, aging and body composition study. J Am Geriatr Soc (2010) 1.16
Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. J Thorac Oncol (2009) 1.12
Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study. PLoS One (2014) 1.10
Quality of life assessment as a predictor of survival in non-small cell lung cancer. BMC Cancer (2011) 1.08
Comorbidities, functional limitations, and geriatric syndromes in relation to treatment and survival patterns among elders with colorectal cancer. J Gerontol A Biol Sci Med Sci (2009) 1.07
Screening older cancer patients for a Comprehensive Geriatric Assessment: A comparison of three instruments. J Geriatr Oncol (2011) 1.03
The value of geriatric assessments in predicting treatment tolerance and all-cause mortality in older patients with cancer. Oncologist (2012) 1.01
Geriatric oncology: an overview of progresses and challenges. Cancer Res Treat (2010) 1.00
Effects of adjuvant chemotherapy on recurrence, survival, and quality of life in stage II colon cancer patients: a 24-month follow-up. Support Care Cancer (2015) 1.00
Photodynamic therapy for the treatment of non-small cell lung cancer. J Thorac Dis (2012) 0.99
Older adults and cancer treatment. Cancer (2008) 0.98
Mentoring junior faculty in geriatric oncology: report from the Cancer and Aging Research Group. J Clin Oncol (2008) 0.97
Influence of medical comorbidities on the presentation and outcomes of stage I-III non-small-cell lung cancer. Clin Lung Cancer (2013) 0.96
Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial. Br J Cancer (2014) 0.95
Geriatric assessment in older patients with breast cancer. J Natl Compr Canc Netw (2009) 0.95
Multiple myeloma in the older adult: better prospects, more challenges. J Clin Oncol (2014) 0.95
The early discontinuation of palliative chemotherapy in older patients with cancer. Support Care Cancer (2013) 0.91
Geriatric assessment in oncology practice. J Am Geriatr Soc (2009) 0.91
Rationale and clinical benefits of an intensive long-term pulmonary rehabilitation program after oesophagectomy: preliminary report. Multidiscip Respir Med (2012) 0.90
Decreased health-related quality of life in women with breast cancer is associated with poor sleep. Behav Sleep Med (2012) 0.90
Functional status declines among cancer survivors: trajectory and contributing factors. J Geriatr Oncol (2014) 0.89
Preoperative and early postoperative quality of life predict survival in potentially curable patients with esophageal cancer. Ann Surg Oncol (2009) 0.88
Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol (2010) 0.86
Non-small cell lung cancer in the elderly: defining treatment options. Semin Oncol (2008) 0.86
Health-related quality of life questionnaires in lung cancer trials: a systematic literature review. Health Econ Rev (2013) 0.86
Assessment and interpretation of comorbidity burden in older adults with cancer. J Am Geriatr Soc (2009) 0.86
Predictive value of initial triage vital signs for critically ill older adults. West J Emerg Med (2013) 0.85
The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. PLoS One (2010) 0.85
Comprehensive geriatric assessment in Korean elderly cancer patients receiving chemotherapy. J Cancer Res Clin Oncol (2010) 0.84
[Expert recommendations 2006 on the rationale for second-line therapy for non-small cell bronchial neoplasms]. Wien Klin Wochenschr (2007) 0.84
First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study. Br J Cancer (2008) 0.84
Systemic therapies for metastatic renal cell carcinoma in older adults. Drugs Aging (2011) 0.83
Baseline quality of life factors predict long term survival after elective resection for colorectal cancer. Int J Surg Oncol (2013) 0.81
Predictors of chemotherapy dose reduction at first cycle in patients age 65 years and older with solid tumors. J Geriatr Oncol (2015) 0.80
Managing breast cancer in the older patient. Clin Adv Hematol Oncol (2013) 0.80
Treatment dilemma in the care of older adults with advanced lung cancer. J Thorac Dis (2016) 0.79
Determining chemotherapy tolerance in older patients with cancer. J Natl Compr Canc Netw (2013) 0.78
Chinese Herbal Medicine for Improving Quality of Life Among Nonsmall Cell Lung Cancer Patients: Overview of Systematic Reviews and Network Meta-Analysis. Medicine (Baltimore) (2016) 0.78
Geriatric assessment factors are associated with mortality after hospitalization in older adults with cancer. Support Care Cancer (2016) 0.78
[Comorbidity oriented oncology - an overview]. Wien Klin Wochenschr (2010) 0.78
Nonclinical Factors Associated with 30-Day Mortality after Lung Cancer Resection: An Analysis of 215,000 Patients Using the National Cancer Data Base. J Am Coll Surg (2015) 0.77
Neural substrate of quality of life in patients with schizophrenia: a magnetisation transfer imaging study. Sci Rep (2015) 0.76
Predicting fatigue in older breast cancer patients receiving radiotherapy. A head-to-head comparison of established assessments. Z Gerontol Geriatr (2015) 0.76
Occupational Therapy for Adults With Cancer: Why It Matters. Oncologist (2016) 0.76
Phase II study of docetaxel and celecoxib, a cyclooxygenase-2 inhibitor, in elderly or poor performance status (PS2) patients with advanced non-small cell lung cancer. J Thorac Oncol (2008) 0.76
The potential role for acupuncture in treating symptoms in patients with lung cancer: an observational longitudinal study. Curr Oncol (2013) 0.76
Comment on 'capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer'. Br J Cancer (2010) 0.75
A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res (2014) 0.75
Quality of Life in Spanish advanced non-small-cell lung cancer patients: determinants of global QL and survival analyses. Springerplus (2016) 0.75
Imagine, scientists can predict my and your survival. Support Care Cancer (2006) 0.75
Achieving a High-Quality Cancer Care Delivery System for Older Adults: Innovative Models of Care. Semin Oncol Nurs (2016) 0.75
Utility of the Edmonton Frail Scale in identifying frail elderly patients during treatment of colorectal cancer. J Gastrointest Oncol (2017) 0.75
The prognostic value of pre-diagnosis health-related quality of life on survival: a prospective cohort study of older Americans with lung cancer. Qual Life Res (2017) 0.75
Comparison of generic and lung cancer-specific quality of life instruments for predictive ability of survival in patients with advanced lung cancer. Springerplus (2016) 0.75
Comprehensive geriatric assessment in the older cancer patient: coming of age in clinical cancer care. Clin Pract (Lond) (2015) 0.75
Patient features predicting long-term survival and health-related quality of life after radical surgery for non-small cell lung cancer. Thorac Cancer (2016) 0.75
Prognostic value of quality of life score in disease-free survivors of surgically-treated lung cancer. BMC Cancer (2016) 0.75
Chemotherapy use and adoption of new agents is affected by age and comorbidities in patients with metastatic colorectal cancer. Cancer (2016) 0.75
Role of uL3 in Multidrug Resistance in p53-Mutated Lung Cancer Cells. Int J Mol Sci (2017) 0.75
Predictors of the multidimensional symptom experience of lung cancer patients receiving chemotherapy. Support Care Cancer (2017) 0.75
Weekly administration of paclitaxel and carboplatin with concurrent thoracic radiation in previously untreated elderly patients with locally advanced non-small-cell lung cancer: A case series of 20 patients. Mol Clin Oncol (2014) 0.75
Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer. Oncol Lett (2017) 0.75
Comprehensive geriatric assessment in 326 older women with early breast cancer. Br J Cancer (2017) 0.75
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 22.04
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol (2010) 13.25
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol (2004) 12.89
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst (2005) 9.10
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol (2004) 8.83
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol (2004) 8.15
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol (2004) 7.36
Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol (2009) 7.04
Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol (2010) 6.87
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol (2005) 6.20
Epidermal growth factor receptor (EGFR) signaling in cancer. Gene (2005) 6.04
Fruit, vegetables, and olive oil and risk of coronary heart disease in Italian women: the EPICOR Study. Am J Clin Nutr (2010) 5.50
Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med (2014) 4.81
Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. Lancet Oncol (2013) 4.55
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst (2011) 4.08
Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis (2013) 4.06
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol (2013) 4.04
Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med (2007) 3.97
Second-line treatment of advanced non-small cell lung cancer. J Thorac Oncol (2008) 3.95
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol (2005) 3.93
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Lancet Oncol (2012) 3.88
Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol (2007) 3.86
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol (2013) 3.67
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2004) 3.54
Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol (2002) 3.53
Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: a randomized double-blind study. J Clin Oncol (2013) 3.49
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol (2008) 3.49
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol (2009) 3.48
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol (2005) 3.48
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst (2003) 3.41
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol (2009) 3.38
Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res (2007) 3.22
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer (2008) 3.19
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.13
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res (2007) 3.12
STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol (2003) 3.04
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. J Clin Oncol (2012) 3.04
Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol (2005) 2.98
Aprepitant for erlotinib-induced pruritus. N Engl J Med (2010) 2.97
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst (2003) 2.95
Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol (2011) 2.92
Detecting disabilities in older patients with cancer: comparison between comprehensive geriatric assessment and vulnerable elders survey-13. J Clin Oncol (2010) 2.89
Gastric cancer. Crit Rev Oncol Hematol (2009) 2.87
Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol (2009) 2.80